Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LJ570
Cat. No.:
0225LY-0840
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
LJ570 is identified as a dual PPAR-alpha/gamma agonist, showing EC50 values of 1.05 uM and 0.12 uM for the respective receptors.
Synonym:
2252488-69-8; (2s)-3-(Biphenyl-4-Yl)-2-(Biphenyl-4-Yloxy)propanoic Acid; (2S)-2-(4-Phenylphenoxy)-3-(4-phenylphenyl)propanoic acid; (2S)-2-{[1,1'-biphenyl]-4-yloxy}-3-{[1,1'-biphenyl]-4-yl}propanoic acid; (S)-3-([1,1'-biphenyl]-4-yl)-2-([1,1'-biphenyl]-4-yloxy)propanoic acid
CAS No.:
2252488-69-8
Compound CID:
73167563
Formula:
C27H22O3
Formula Weight:
394.46
Specification
Targets&IC50:
PPARα: 1.05 μM (EC50) ; PPARγ: 0.12 μM (EC50)
Relative Density:
1.185 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LJ570 can be used in signaling research to explore the selective inhibition of lipid-related enzyme pathways.
Library Information
Target:
PPAR
Receptor:
PPAR
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
g9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
9 mg/mL; 22.82 mM
